Abstract PS8-03: Exploratory biomarker analysis of Trastuzumab deruxtecan (T-DXd) vs Trastuzumab emtansine (T-DM1) efficacy in human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC) in DESTINY-Breast03 (DB-03)
William Jacot(Inserm), Erika Hamilton(Sarah Cannon), Giuseppe Curigliano(European Institute of Oncology), Sara Hurvitz, Sherene Loi(The University of Melbourne), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Thomas Bachelot(Centre Léon Bérard), Seock‐Ah Im(Seoul National University), Hiroji Iwata(Nagoya City University), Vinit Kumar, Yusuke Kuwahara, Anton Egorov(Daiichi Sankyo (United States)), Javier Cortés, Aislyn Boran(Daiichi Sankyo (United States))
Cited by 2
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k